Conference abstract · 2018
Research articlePublished 2011
Increasing Oxygen in Hypoxic Tumors
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Tumors are frequently hypoxic, affecting both chemotherapy and radiotherapy. Trans sodium crocetinate (TSC), a novel pharmaceutical agent, causes increases in oxygen levels of hypoxic tissues. It has also been shown, in animal models of cancer, that radiotherapy is more effective when used in conjunction with TSC. An increase in tumor oxygen should also affect the HIF-1α pathway. Thus, an in vitro study of that pathway in human glioblastoma cells was performed. Methods: This study involved the use of quantitative real time polymerase chain reaction technology and human glioblastoma multiforme cells. The cells were cultured under both hypoxic and normoxic conditions. Results: The inclusion of TSC in the media of the cells resulted in some genes in the HIF-1α pathway being either up- or down-regulated in a statistically-significant manner. These changes were opposite to those which occurred when the same cells were grown under hypoxic conditions but without TSC. In addition, those same genes reacted in an opposite manner when the cells were grown with TSC but under a normal oxygen environment. Conclusions: These results support previous observations that TSC reduces hypoxia in tumor cells. Since TSC caused statistical differences in gene expression under hypoxia different from those caused under normoxia, it suggests that there is not a direct effect of TSC on the HIF-1α pathway. Rather, TSC alters the gene expression due to a change in the response of the genes to different oxygen levels. These data also correlate with previous in vivo studies which show that TSC increases oxygen to hypoxic tissue but not to normal tissue. Thus, these data, combined with previous studies of animal cancer models, strongly suggest that TSC has the ability to increase cellular oxygen in tumor cells. Such a physiological change can be beneficial with combined with radiotherapy for cancer.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 24 Aug 2015
Molecular oxygen delivery to hypoxic tumors by ultrasound triggering
Conference abstract · 24 Aug 2015
Molecular oxygen delivery to hypoxic tumors by ultrasound triggering
Editorial · 29 Apr 2021
Oxygen Sensing: Hydroxylation of HIF-1
Commentary · 30 May 2022
Increasing Tenascin-C-targeted Drug Delivery to Tumors Previously Subjected to Therapy
More from this journal
The newest in Journal of Clinical & Experimental Pharmacology.
Article · 9 Nov 2026
Balancing Efficacy and Tolerability in Nasal Decongestion: A Rationale for the Oxymetazoline and Dexpanthenol Combination
Article · 23 Feb 2026
A Thorough Overview of Polycystic Ovary Syndrome (PCOS) in Female Rats
Article · 19 Dec 2025
Theoretical Pharmacology: Understanding Drug Action Through Models and Principles
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Pharmacology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “John L. Gainer”
- BylineArticles whose byline prints “Miles F. Lankford”

